Maravai LifeSciences (MRVI) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 125.5% versus a loss of 14.4%. Over five years, VRDN leads with a +9.3% price change compared with -79.9% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.76 billion vs $2.11 billion), about 1.3 times the size, while Viridian Therapeutics is growing revenue faster (+23359.9% vs -28.3%).
Maravai LifeSciences converts more of its revenue into profit, with a net margin of -70.4% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | VRDN |
|---|---|---|
| Share price | $7.44 | $18.66 |
| Market cap | $2.76B | $2.11B |
| 1-day change | +3.19% | +1.74% |
| YTD return | +128.92% | -40.04% |
| 1-year return | +125.45% | -14.44% |
| 5-year return | -79.94% | +9.31% |
| EPS (TTM) | $-0.53 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | $70.85M |
| Revenue growth (YoY) | -28.34% | +23359.93% |
| Net income (latest FY) | $-130.77M | $-342.60M |
| Gross margin | 18.30% | — |
| Operating margin | -115.89% | -512.91% |
| Net margin | -70.41% | -483.57% |
| 52-week high | $9.42 | $34.29 |
| 52-week low | $2.55 | $13.18 |
| Distance from 52-week high | -21.02% | -45.58% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +5.24% | +96.95% |
| Average volume | 3.33M | 1.71M |
| Shares outstanding | 148.99M | 113.29M |
| Employees | 415 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed VRDN by 139.9 percentage points over the past year.
- Maravai LifeSciences is more profitable, keeping -70.4 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs -28.34%).
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
MRVI vs VRDN FAQ
Which is bigger, Maravai LifeSciences or Viridian Therapeutics?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.76B compared with $2.11B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, MRVI or VRDN?
MRVI returned +125.45% over the past 12 months, compared with -14.44% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.